LinkGevity, an AI-driven biotech company focused on healthspan and age-related diseases, has been selected for the prestigious KQ Labs Programme at the Francis Crick Institute.

This highly selective initiative supports only 10 startups annually, providing them with equity investment and access to a global scientific network.

Founded by sisters Dr. Carina Kern and Serena Kern-Libera, LinkGevity aims to tackle age-related diseases by addressing aging at its biological source.

This innovative therapeutic has received funding from the Horizon Europe grant and the UK government, underscoring its potential impact.

LinkGevity utilizes Dr. Kern's Blueprint Theory of Aging to identify molecular pathways responsible for aging and develop broad-spectrum therapeutics.

Their advanced computational techniques map the biological triggers of aging and identify therapeutic targets through data analysis.

The company is based at the Babraham Research Campus affiliated with the University of Cambridge, where it seeks to transform healthcare through innovative science.

LinkGevity plans to initiate its first clinical trial later in 2025, targeting kidney-related tissue degeneration, which is a significant global health issue.

CEO Dr. Kern highlighted the importance of the KQ Labs Programme for their plans to treat kidney disease, a leading global cause of death, while COO Kern-Libera noted its potential to enhance their research efforts.

The company's flagship product, Anti-Necrotic™, is a first-in-class therapeutic designed to inhibit necrosis, which is linked to accelerated aging and chronic diseases, particularly in acute kidney disease.

Serena Kern-Libera emphasized the recognition of their therapeutic and the momentum gained from participation in the NASA/Microsoft Space-Health Programme.

The KQ Labs Programme not only provides investment but also fosters connections to advance data-driven healthcare innovations.